Purpose Of Review: Intralymphatic immunotherapy (ILIT) is a promising novel method of immunotherapy, that is short and convenient, and may be very effective. Results have been varied, and efforts to unravel the real value of the treatment are ongoing. Methods used to assess the effect in clinical trials have been so varied that it is difficult to compare studies with each other.
Recent Findings: Some advances have been made; the importance of injecting into the lymph node has been illustrated, and treatment with a range of medicines has proven to be successful. In meta-analyses the treatment has been shown to have no serious side effects and to be an effective short term desensitizing agent. Now it remains to be shown that ILIT also has long-term effects of tolerance. Preliminary data suggest that there is a long-term effect.
Summary: Injecting allergen directly into a lymph node strengthens the protective immune response. ILIT is safe and induces desensitization and very likely also induces tolerance. Compliance will improve compared with other treatment forms. If ILIT holds its promise, it will become an attractive option for patients with allergy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ACI.0000000000000857 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial.
Int J Mol Sci
January 2025
Division of Pediatrics, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, 581 83 Linköping, Sweden.
Immunotherapies aimed at preserving residual beta cell function in type 1 diabetes have been successful, although the effect has been limited, or raised safety concerns. Transient effects often observed may necessitate redosing to prolong the effect, although this is not always feasible or safe. Treatment with intralymphatic GAD-alum has been shown to be tolerable and safe in persons with type 1 diabetes and has shown significant efficacy to preserve C-peptide with associated clinical benefit in individuals with the human leukocyte antigen DR3DQ2 haplotype.
View Article and Find Full Text PDFNovel Approaches to Allergen Immunotherapy for Respiratory Allergies.
Pharmaceuticals (Basel)
November 2024
Division of Allergy and Clinical Immunology, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Allergen immunotherapy (AIT) remains the cornerstone for managing respiratory allergies, offering long-term symptom relief, disease modification, and prevention of disease progression. While novel approaches like intralymphatic and epicutaneous immunotherapy and the combination of allergens with adjuvants show promise, traditional methods remain effective and safe. Hypoallergenic T-cell peptide vaccines and recombinant allergens require further research to confirm their clinical benefits.
View Article and Find Full Text PDFIs intralymphatic immunotherapy effective and safe for allergic rhinitis?: A meta-analysis.
Medicine (Baltimore)
November 2024
Department of Otorhinolaryngology Head and Neck Surgery, Nanchong Central Hospital, The Second Clinical Medical College, Nanchong, China.
Article Synopsis
- A systematic review and meta-analysis investigated the effectiveness and safety of intralymphatic immunotherapy (ILIT) for treating allergic rhinitis (AR), considering data collected until September 2023.
- The analysis included 11 randomized control studies with 406 patients, showing that ILIT significantly improved patients' quality of life and reduced adverse nasal symptoms compared to control groups.
- However, no significant differences were observed in various symptom scores, and the authors emphasized the need for further high-quality research to validate these findings.
Recent developments in immunotherapy approaches for allergic rhinitis.
World J Clin Cases
November 2024
Drug Clinical Trial Unit, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
Article Synopsis
- Allergic rhinitis (AR) is a global health issue that can lead to asthma, affecting patients' quality of life, but immunotherapy shows promise in relieving symptoms and addressing underlying causes.
- This article reviews various immunotherapy approaches for AR, including subcutaneous, sublingual, oral, intralymphatic, and innovative intravenous treatments, detailing their mechanisms and clinical relevance.
- The comprehensive analysis provided aims to enhance understanding of immunotherapy's role in AR management and serve as a reference for clinical treatment strategies.
Intralymphatic Immunotherapy with Ultrasound Guidance Seems to Be Associated with Improved Clinical Effect in Canine Atopic Dermatitis-A Retrospective Study of 109 Cases.
Animals (Basel)
October 2024
Dermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland.
Intralymphatic immunotherapy (ILIT) has been used successfully in both human and veterinary medicine as a safe and effective treatment for allergic diseases. Initially, ILIT was administered by ultrasound guidance, but palpation-based injections have become more popular among veterinary dermatologists. Data from human medicine, however, show that precise injection into the lymph node is mandatory, and injection quality clearly correlates with clinical response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!